Overview
Lobbying Costs
300,000€ - 399,999€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
1.25 Fte (2)
Lobbyists with EP accreditation
1
High-level Commission meetings
7
Lobbying Costs over the years
-
Info
Illumina, Inc.
EU Transparency Register
547949121038-83 First registered on 11 Mar 2016
Goals / Remit
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Main EU files targeted
Illumina follows policy and legislative developments related to genomics, agri-genomics, public health, animal health, agriculture, forensics, biotechnology, data protection, science, and research policies.
In particular, Illumina follows the discussions on the proposal for a EU Health Data Space (EHDS) and developments relating to the Regulations on medical devices (MDR) and In-vitro diagnostics (IVDR). It also engages in policy and regulatory initiatives relating to research and innovation in the EU (Horizon Europe), including more generally developments relating to EU research programs, with a focus on genomics research.
Additionally, Illumina focuses on policy developments related to the Beating Cancer Plan, the 1+Million Genomes Initiative, the EU Action on Antimicrobial Resistance (AMR), the EU Covid-19 policy response, the implementation of the NextGenerationEU Plan, and the EU orphan medicines legislation.
Moreover, an emphasis is also given to monitoring the review in scope and responsibilities of key institutional stakeholders such as the European Medicine Agency (EMA), the European Center for Disease Control (ECDC) and the European Health Emergency preparedness and Response Authority (HERA).Address
Head Office
5200 Illumina Way
San Diego CA 92122
UNITED STATESEU Office
Rue d'Arlon, 25Topos - Illumina Inc.
Brussels 1050
BELGIUMWebsite
-
People
Total lobbyists declared
2
Employment time Lobbyists 100% 1 25% 1 Lobbyists (Full time equivalent)
1.25
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
1 accreditations were / are live (in bold) for the selected state of 03 Dec 2024
Name Start date End Date Federico PISANI 04 Nov 2024 03 Nov 2025 Marie Helene FANDEL 18 Oct 2023 04 Oct 2024 Federico PISANI 17 Aug 2023 17 Aug 2024 Mr Jan NEUTZE 17 Dec 2022 16 Dec 2023 Federico PISANI 31 Aug 2022 17 Aug 2023 Miriam GARGESI 09 Aug 2022 05 Aug 2023 Miriam GARGESI 10 Oct 2018 10 Oct 2019 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
MedTech Europe https://www.medtecheurope.org/
Eucope https://www.eucope.org/
All.Can https://www.all-can.org/
European Cancer Organisation https://www.europeancancer.org/
American Chamber of Commerce to the EU https://www.amchameu.eu/
American European Community Association (AECA) https://aeca.org/Member organisations
See above
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
300,000€ - 399,999€
Major contributions in closed year
None declared
Intermediaries for closed year
None declaredIntermediaries for current year
None declaredClosed year Costs
300,000€ - 399,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
None declared
Groups (European Parliament)
N/A
Communication activities
None declared
Other activities
None declared
Meetings
Meetings
7 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 03 Dec 2021 Location Brussels Subject Presentation of the merger case Illumina and Grail Cabinet Cabinet of Commissioner Elisa Ferreira Portfolio Cohesion and Reforms Attending - Carole Mancel-Blanchard (Cabinet member)
-
Date 03 Dec 2021 Location Brussels, Belgium Subject The public health benefits and competition issues arising out of the merger between Illumina and GRAIL Cabinet Cabinet of Commissioner Janusz Wojciechowski Portfolio Agriculture Attending - Joanna Stawowy (Cabinet member)
-
Date 03 Dec 2021 Location Video-conference Subject Presentation of an early screening test by a cancer screening start-up. Its impact on health, early detection of cancer and especially on most vulnerable groups was discussed in the context of equality policy and the EU Beating Cancer strategy Cabinet Cabinet of Commissioner Helena Dalli Portfolio Equality Attending - Eva Gerhards (Cabinet member)
-
Date 03 Dec 2021 Location Brussels Subject Healthcare benefits of Cancer test Cabinet Cabinet of Vice-President Margaritis Schinas Portfolio Promoting the European Way of Life Attending - Chris Uregian (Cabinet member)
-
Date 03 Dec 2021 Location Virtual Subject Cancer Screening tests, Illumina-GRAIL Merger Cabinet Cabinet of Commissioner Mairead Mcguinness Portfolio Financial services, financial stability and Capital Markets Union Attending - Katherine Power (Cabinet member)
-
Date 12 Nov 2021 Location Videconference Subject Challenges of the health industrial ecosystem Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Maurits-Jan Prinz (Cabinet member)
-
Date 29 Sep 2021 Location Brussels (virtual) Subject Illumina/GRAIL transaction, which in addition to important competition policy questions Cabinet Cabinet of President Ursula von der Leyen Portfolio President Attending - Anthony Whelan (Cabinet member)
Other Lobbyists